| 10.13 0.57 (5.96%) | 06-30 16:00 | |||||||||||||
|
|
| Short term |   |
|||
| Mid term |  |
|||
| Targets | 6-month : | 12.4  |
1-year : | 13.74 |
| Resists | First : | 10.61 |
Second : | 11.76 |
| Pivot price | 9.51 |
|||
| Supports | First : | 8.76 | Second : | 7.28 |
| MAs | MA(5) : | 9.75 |
MA(20) : | 9.6 |
| MA(100) : | 10.29 |
MA(250) : | 9.15 |
|
| MACD | MACD : | -0.3 |
Signal : | -0.3 |
| %K %D | K(14,3) : | 63.7 |
D(3) : | 55 |
| RSI | RSI(14): 52.4 |
|||
| 52-week | High : | 12.4 | Low : | 5.05 |
Price has closed above its short-term moving average. Short-term moving average is currently below mid-term; and below long-term moving average. From the relationship between price and moving averages: This stock is NEUTRAL in short-term; and NEUTRAL in mid-long term.[ IMTX ] has closed below upper band by 6.7%. Bollinger Bands are 7.9% narrower than normal. The current width of the bands does not suggest anything about the future direction or movement of prices.
| If tomorrow: | Open lower | Open higher |
| High: | 9.7 - 9.75 | 9.75 - 9.8 |
| Low: | 9.18 - 9.23 | 9.23 - 9.28 |
| Close: | 9.48 - 9.56 | 9.56 - 9.64 |
Immatics N.V. is a clinical-stage biopharmaceutical firm dedicated to discovering and advancing T-cell receptor (TCR) based immunotherapies aimed at combating cancer, primarily within the United States. Its therapeutic strategy centers on targeted immunotherapies for solid tumors, utilizing two distinct approaches: adoptive cell therapies (ACT) and antibody-like TCR Bispecifics. The company's ACTengine™ portfolio features several candidates in Phase I clinical trials. These include IMA201, designed to recognize melanoma-associated antigens 4 or 8 in solid tumor patients; IMA202, which targets melanoma-associated antigen 1 across various solid tumor types, such as squamous non-small cell lung carcinoma and hepatocellular carcinoma; and IMA203, aimed at preferentially expressed antigen in melanoma in adult patients with recurrent or treatment-resistant solid tumors. Additionally, IMA204, currently in preclinical stages, focuses on targeting tumor stroma cells. In its preclinical TCR Bispecifics pipeline, Immatics is advancing IMA401, which targets cancer testis antigens for solid tumor indications, and IMA402, also under investigation for solid tumor therapies. Other programs include IMA101 for cancer treatment and IMA301, an allogeneic cellular therapy candidate. Immatics has established strategic partnerships to bolster its development efforts. These include collaborations with GlaxoSmithKline Intellectual Property Development Limited for novel adoptive cell therapies across various cancer indications; MD Anderson Cancer Center for multiple T-cell and TCR-based adoptive cellular therapies; Celgene Switzerland LLC for additional novel adoptive cell therapies; and Genmab A/S to develop T-cell engaging bispecific immunotherapies for diverse cancer indications. The company's headquarters are situated in Tübingen, Germany.
Mon, 29 Jun 2026
Immatics N.V. Actuals & Estimates (NASDAQ:IMTX) - TradingView
Sun, 28 Jun 2026
Price to sales forward of Immatics N.V. – NASDAQ:IMTX - TradingView
Sat, 27 Jun 2026
IMTX Forecast — Price Target — Prediction for 2027 - TradingView
Fri, 19 Jun 2026
Immatics Shareholders Approve All Proposals at June 18, 2026 AGM - The Globe and Mail
Thu, 18 Jun 2026
Immatics (IMTX) director receives grant of 48,000 stock options at $9.09 - Stock Titan
Thu, 18 Jun 2026
Immatics N.V. (IMTX) grants director options on 48,000 ordinary shares - Stock Titan
| Price to Book Value: P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly. |
Neutral |
| Price to Earnings: PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS). |
Underperform |
| Discounted cash flow: DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows. |
Underperform |
| Return on Assets: ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit. |
Underperform |
| Return on Equity: ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency. |
Underperform |
| Debt to Equity: evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn. |
Neutral |
|
Exchange:
NASDAQ
|
|
|
Sector:
Healthcare
|
|
|
Industry:
Biotechnology
|
|
| Shares Out | 137 (M) |
| Shares Float | 70 (M) |
| Held by Insiders | 17.5 (%) |
| Held by Institutions | 79.6 (%) |
| Shares Short | 5,640 (K) |
| Shares Short P.Month | 4,800 (K) |
| EPS | -1.95 |
| EPS Est Next Qtrly | 0 |
| EPS Est This Year | 0 |
| EPS Est Next Year | 0 |
| Book Value (p.s.) | 3.8 |
| Profit Margin | 0 % |
| Operating Margin | -867.9 % |
| Return on Assets (ttm) | -22.5 % |
| Return on Equity (ttm) | -43.3 % |
| Qtrly Rev. Growth | -59 % |
| Gross Profit (p.s.) | -1.2 |
| Sales Per Share | 0.27 |
| EBITDA (p.s.) | -1.5 |
| Qtrly Earnings Growth | 0 % |
| Operating Cash Flow | -184 (M) |
| Levered Free Cash Flow | -111 (M) |
| PE Ratio | -5.23 |
| PEG Ratio | 0 |
| Price to Book value | 2.65 |
| Price to Sales | 37.11 |
| Price to Cash Flow | -7.51 |
| Dividend | 0 |
| Forward Dividend | 0 |
| Dividend Yield | 0% |
| Dividend Pay Date | Invalid DateTime. |
| Ex-Dividend Date | Invalid DateTime. |
|
|
|
|
|
|
|
|
|